Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1 alpha

null A.a. Aljabali; Hamid Bakshi; null L. Hakkim; null A. Haggag; Khalid M. Al-Batanyeh; null S. Al Zoubi; Bahaa Al-trad; Mohamad Nasef; Saurabh Satija; Meenu Mehta; Kavita Pabreja; Vijay Mishra; Mohammed Khan; Salem Abobaker; Ibrahim M. Azzouz; Harish Dureja; Ritesh M. Pabari; Ashref Ali K. Dardouri; Prashant Kesharwani; Gaurav Gupta; Shakti Dhar Shukla; Parteek Prasher; Nitin B. Charbe; Poonam Negi; Deepak N. Kapoor; Dinesh Kumar Chellappan; Mateus Webba da Silva; Paul Thompson; Kamal Dua; Paul McCarron; Murtaza Tambuwala

doi:10.3390/cancers12010113

Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1 alpha

A.a. Aljabali, Hamid Bakshi, L. Hakkim, A. Haggag, Khalid M. Al-Batanyeh, S. Al Zoubi, Bahaa Al-trad, Mohamad Nasef, Saurabh Satija, Meenu Mehta, Kavita Pabreja, Vijay Mishra, Mohammed Khan, Salem Abobaker, Ibrahim M. Azzouz, Harish Dureja, Ritesh M. Pabari, Ashref Ali K. Dardouri, Prashant Kesharwani, Gaurav Gupta Shakti Dhar Shukla, Parteek Prasher, Nitin B. Charbe, Poonam Negi, Deepak N. Kapoor, Dinesh Kumar Chellappan, Mateus Webba da Silva, Paul Thompson, Kamal Dua, Paul McCarron, Murtaza Tambuwala

Research output: Contribution to journal › Article › peer-review

81 Citations (Scopus)

96 Downloads (Pure)

Abstract

Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

Original language	English
Article number	113
Pages (from-to)	1-22
Journal	Cancers
Volume	12
Issue number	1
DOIs	https://doi.org/10.3390/cancers12010113
Publication status	Published (in print/issue) - 1 Jan 2020

Keywords

Albumin nanoparticles
Colon cancer
HIF-1α
Nuclear P65
Piceatannol

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers12010113Licence: CC BY

final published versionFinal published version, 4.87 MBLicence: CC BY

Cite this

A.a. Aljabali, Bakshi, H., L. Hakkim, A. Haggag, Al-Batanyeh, K. M., S. Al Zoubi, Al-trad, B., Nasef, M., Satija, S., Mehta, M., Pabreja, K., Mishra, V., Khan, M., Abobaker, S., Azzouz, I. M., Dureja, H., Pabari, R. M., Dardouri, A. A. K., Kesharwani, P., ... Tambuwala, M. (2020). Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1 alpha. Cancers, 12(1), 1-22. Article 113. https://doi.org/10.3390/cancers12010113

@article{89dc08fef4154705bff8d8564ed81306,

title = "Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1 alpha",

abstract = "Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.",

keywords = "Albumin nanoparticles, Colon cancer, HIF-1α, Nuclear P65, Piceatannol",

author = "{A.a. Aljabali} and Hamid Bakshi and {L. Hakkim} and {A. Haggag} and Al-Batanyeh, {Khalid M.} and {S. Al Zoubi} and Bahaa Al-trad and Mohamad Nasef and Saurabh Satija and Meenu Mehta and Kavita Pabreja and Vijay Mishra and Mohammed Khan and Salem Abobaker and Azzouz, {Ibrahim M.} and Harish Dureja and Pabari, {Ritesh M.} and Dardouri, {Ashref Ali K.} and Prashant Kesharwani and Gaurav Gupta and {Dhar Shukla}, Shakti and Parteek Prasher and Charbe, {Nitin B.} and Poonam Negi and Kapoor, {Deepak N.} and Chellappan, {Dinesh Kumar} and {Webba da Silva}, Mateus and Paul Thompson and Kamal Dua and Paul McCarron and Murtaza Tambuwala",

year = "2020",

month = jan,

day = "1",

doi = "10.3390/cancers12010113",

language = "English",

volume = "12",

pages = "1--22",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "1",

}

A.a. Aljabali, Bakshi, H, L. Hakkim, A. Haggag, Al-Batanyeh, KM, S. Al Zoubi, Al-trad, B, Nasef, M, Satija, S, Mehta, M, Pabreja, K, Mishra, V, Khan, M, Abobaker, S, Azzouz, IM, Dureja, H, Pabari, RM, Dardouri, AAK, Kesharwani, P, Gupta, G, Dhar Shukla, S, Prasher, P, Charbe, NB, Negi, P, Kapoor, DN, Chellappan, DK, Webba da Silva, M, Thompson, P, Dua, K, McCarron, P & Tambuwala, M 2020, 'Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1 alpha', Cancers, vol. 12, no. 1, 113, pp. 1-22. https://doi.org/10.3390/cancers12010113

TY - JOUR

T1 - Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1 alpha

AU - A.a. Aljabali, null

AU - Bakshi, Hamid

AU - L. Hakkim, null

AU - A. Haggag, null

AU - Al-Batanyeh, Khalid M.

AU - S. Al Zoubi, null

AU - Al-trad, Bahaa

AU - Nasef, Mohamad

AU - Satija, Saurabh

AU - Mehta, Meenu

AU - Pabreja, Kavita

AU - Mishra, Vijay

AU - Khan, Mohammed

AU - Abobaker, Salem

AU - Azzouz, Ibrahim M.

AU - Dureja, Harish

AU - Pabari, Ritesh M.

AU - Dardouri, Ashref Ali K.

AU - Kesharwani, Prashant

AU - Gupta, Gaurav

AU - Dhar Shukla, Shakti

AU - Prasher, Parteek

AU - Charbe, Nitin B.

AU - Negi, Poonam

AU - Kapoor, Deepak N.

AU - Chellappan, Dinesh Kumar

AU - Webba da Silva, Mateus

AU - Thompson, Paul

AU - Dua, Kamal

AU - McCarron, Paul

AU - Tambuwala, Murtaza

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

AB - Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

KW - Albumin nanoparticles

KW - Colon cancer

KW - HIF-1α

KW - Nuclear P65

KW - Piceatannol

UR - https://pure.ulster.ac.uk/en/publications/albumin-nano-encapsulation-of-piceatannol-enhances-its-anticancer

UR - https://www.mdpi.com/2072-6694/12/1/113

UR - https://www.ncbi.nlm.nih.gov/pubmed/?term=31906321

UR - http://www.scopus.com/inward/record.url?scp=85077603084&partnerID=8YFLogxK

U2 - 10.3390/cancers12010113

DO - 10.3390/cancers12010113

M3 - Article

C2 - 31906321

SN - 2072-6694

VL - 12

SP - 1

EP - 22

JO - Cancers

JF - Cancers

IS - 1

M1 - 113

ER -

Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1 alpha

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Paul Mc Carron

Cite this

Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1 alpha

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Profiles

Paul Mc Carron

Cite this